Keratonosus
Conditions
Interventions
1. Early intervention subgroup of the active stage group :Aflibercept injection into the corneal stroma within <=7 days after the occurrence of CNV
2. The delayed intervention subgroup of the active stage group :Aflibercept was injected into the corneal stroma 8-14 days after the occurrence of CNV
3. Early intervention subgroup of the stable period group :Aflibercept injection into the corneal stroma <=1 month after CNV stabilization
4. The delayed intervention subgroup of the stable period group :Aflibercept was injected into the corneal stroma 2-3 months after the CNV stabilized
Sponsors
Wuhan Aier Hankou Eye Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Subjects must meet all of the following inclusion criteria at the time of screening: 1. Age >=18 years and =2mm into the limbus; for patients with bilateral involvement, the more severe eye is included; 3. CNV patients caused by bacterial, fungal, or viral corneal infections or eyelid-related keratoconjunctivitis; 4. Diagnostic criteria for active CNV: New CNV within 3 weeks, with corneal edema and inflammatory cell infiltration; Diagnostic criteria for stable CNV: Vascular stability >=3 months after CNV formation, with no active corneal inflammation; 5. Best corrected visual acuity <=0.5; 6. Signed informed consent form.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria during screening will not be eligible for enrollment in this study: 1. Individuals aged 75 years; 2. Individuals with a history of intraocular anti-VEGF drug injection; 3. Individuals allergic to aflibercept; 4. Individuals with a history of persistent corneal epithelial defects or eye surgery within the past 3 months, or those with other eye diseases, such as a history of heat or chemical injury; 5. Individuals with severe systemic diseases, such as pemphigoid, Stevens-Johnson syndrome, Sjögren's syndrome, or other severe autoimmune diseases or serious illnesses; 6. Pregnant, breastfeeding, or women planning to become pregnant; 7. Individuals who cannot be followed up regularly.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The area of corneal neovascularization;Anterior segment optical coherence tomography angiography;Tear concentrations of VEGF, IL-6, and MMP-9; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intraocular pressure;Vision;Corneal thickness;In vivo laser scanning confocal microscopy; | — |
Countries
China
Contacts
Public ContactQingyan Zeng
Wuhan Aier Hankou Eye Hospital
Outcome results
None listed